- An experienced dermatopathologist is an important member of the multidisciplinary melanoma team:
- That contributes to the accurate diagnosis and staging of patients with melanoma
- It is my practice to have outside biopsies reviewed by our pathology staff upon referral to confirm diagnosis
- Although the pathologic analysis primarily consists of microscopic examination of hematoxylin- and eosin-stained tumor:
- Several melanocytic cell markers may also be useful to confirm the diagnosis
- Two antibodies that have been widely used in immunohistochemical evaluations are:
- S-100 and HMB-45:
- S-100 is expressed not only by more than 90% of melanomas:
- But also by several other tumors and some normal tissues, including dendritic cells
- In contrast, the monoclonal antibody HMB-45:
- Is relatively specific (yet not as sensitive) for proliferative melanocytic cells and melanoma
- It is therefore often used as a confirmatory stain when the diagnosis of melanoma is being considered
- S-100 is expressed not only by more than 90% of melanomas:
- Anti–MART-1 staining has also been shown to be very useful in the diagnosis of melanoma
- The major histomorphologic components that should be included in a primary melanoma pathology report include:
- Breslow thickness
- Ulceration status
- Peripheral and deep margin status
- Mitotic rate:
- Using the dermal hot spot approach with units of mitoses per mm2
- Other features that are often also recorded include:
- Presence of microsatellites
- Histologic subtype
- Lymphovascular invasion
- Tumor-infiltrating lymphocytes (TIL)
- Regression
- Neurotropism
- Growth phase
- The absence of epidermal component:
- As the latter may represent an uncommon dermal primary or a metastatic deposit
- S-100 and HMB-45:
- The major histomorphologic types of melanoma:
- Superficial spreading melanomas:
- Constitute the majority of melanomas:
- Approximately 70% of melanomas
- Generally arise in a pre-existing nevus
- Constitute the majority of melanomas:
- Superficial spreading melanomas:
- Nodular melanomas:
- Are the second most common type:
- 15% to 30% of melanoma
- Nodular melanomas progress to invasiveness more quickly than other types:
- However, when depth of the melanoma is controlled for:
- Nodular melanomas are generally associated with the same prognosis as other lesions
- However, when depth of the melanoma is controlled for:
- Are the second most common type:
- Lentigo maligna melanomas:
- Constitute a small percentage of melanomas:
- 4% to 10%
- These lesions occur in sun-exposed areas
- Lentigo maligna melanomas are classically located on:
- The faces of older white women
- In general, lentigo maligna melanomas are:
- Large (> 3 cm at diagnosis)
- Flat lesions
- Are uncommon in individuals younger than 50 years
- Given their often-ill-defined appearance:
- Margin control can sometimes be challenging at the time of wide excision
- Constitute a small percentage of melanomas:
- Acral lentiginous melanomas:
- Occur on the palms (palmar), soles (plantar), or beneath the nail beds (subungual):
- Although not all palmar, plantar, and subungual melanomas are acral lentiginous melanomas
- These melanomas account for only 2% to 8% of melanomas in white patients but for a substantially higher proportion of melanomas (35% to 60%) in darker-skinned patients
- They are often large:
- With an average diameter of approximately 3 cm
- Occur on the palms (palmar), soles (plantar), or beneath the nail beds (subungual):
- Amelanotic melanomas:
- Are relatively uncommon melanomas that occur without pigmentation changes
- They are often more difficult to diagnose because of their lack of pigmentation
- Factors such as:
- Change in size
- Asymmetry
- Irregular borders may suggest malignancy and prompt a biopsy, but delays in diagnosis may sometimes be observed
- While melanoma has been traditionally described using these categories:
- Prognosis is more dependent upon staging than by these histomorphologic types

#Arrangoiz #CancerSurgeon #HeadandNeckSurgeon #SurgicalOncologist #Melanoma #SkinCancer #CASO #CenterforAdvancedSurgicalOncology